相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis
Matthias Woelfl et al.
BLOOD (2013)
Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy
S. Mustjoki et al.
LEUKEMIA (2013)
Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40
Yan Yang et al.
BLOOD (2012)
Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
A. P. Algazi et al.
BRITISH JOURNAL OF CANCER (2012)
Hypoxia-Inducible miR-210 Regulates the Susceptibility of Tumor Cells to Lysis by Cytotoxic T Cells
Muhammad Zaeem Noman et al.
CANCER RESEARCH (2012)
Myeloid-derived Suppressor Cells Adhere to Physiologic STAT3- vs STAT5-dependent Hematopoietic Programming, Establishing Diverse Tumor-Mediated Mechanisms of Immunologic Escape
Peter A. Cohen et al.
IMMUNOLOGICAL INVESTIGATIONS (2012)
Combined vaccine plus axitinib therapy yields superior antitumor efficacy in a murine melanoma model
Anamika Bose et al.
MELANOMA RESEARCH (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Activity and Safety of Dasatinib as Second-Line Treatment or in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
Massimo Breccia et al.
BIODRUGS (2011)
A Phase 2 Trial of Dasatinib in Advanced Melanoma
Harriet M. Kluger et al.
CANCER (2011)
Antiangiogenic Agent Sunitinib Transiently Increases Tumor Oxygenation and Suppresses Cycling Hypoxia
Shingo Matsumoto et al.
CANCER RESEARCH (2011)
Blocking Hypoxia-Induced Autophagy in Tumors Restores Cytotoxic T-Cell Activity and Promotes Regression
Muhammad Zaeem Noman et al.
CANCER RESEARCH (2011)
PGE2-Induced CXCL12 Production and CXCR4 Expression Controls the Accumulation of Human MDSCs in Ovarian Cancer Environment
Natasa Obermajer et al.
CANCER RESEARCH (2011)
Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors
Juan Carlos Montero et al.
CLINICAL CANCER RESEARCH (2011)
Targeting immune suppressing myeloid-derived suppressor cells in oncology
Johnny Kao et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2011)
Novel Immunotherapeutic Agents and Small Molecule Antagonists of Signalling Kinases for the Treatment of Metastatic Melanoma
Nagendra Natarajan et al.
DRUGS (2011)
Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination
Anamika Bose et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Hypoxia-Dependent Inhibition of Tumor Cell Susceptibility to CTL-Mediated Lysis Involves NANOG Induction in Target Cells
Meriem Hasmim et al.
JOURNAL OF IMMUNOLOGY (2011)
Intratumoral IL-12 Gene Therapy Results in the Crosspriming of Tc1 Cells Reactive Against Tumor-associated Stromal Antigens
Xi Zhao et al.
MOLECULAR THERAPY (2011)
Current Status of Src Inhibitors in Solid Tumor Malignancies
Lauren N. Puls et al.
ONCOLOGIST (2011)
Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers
Max Yan et al.
BREAST CANCER RESEARCH (2011)
A Case of Acute Colitis with Severe Rectal Bleeding in a Patient with Chronic Myeloid Leukemia after Dasatinib Use
Murat Erkut et al.
ACTA HAEMATOLOGICA (2010)
Targeting STAT3 in Adoptively Transferred T Cells Promotes Their In Vivo Expansion and Antitumor Effects
Maciej Kujawski et al.
CANCER RESEARCH (2010)
Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy
Peter Rohon et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Dasatinib in solid tumors
Lori C. Kim et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Safety profiles of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia
Sara M. Tinsley
JOURNAL OF CLINICAL NURSING (2010)
Effect of Pazopanib on Tumor Microenvironment and Liposome Delivery
Tina D. Tailor et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Lck is a key target of imatinib and dasatinib in T-cell activation
K. C. Lee et al.
LEUKEMIA (2010)
Dasatinib inhibits the proliferation and function of CD4(+)CD25(+) regulatory T cells
Fei Fei et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Tumor Vascular Changes Mediated by Inhibition of Oncogenic Signaling
Naseer Qayum et al.
CANCER RESEARCH (2009)
The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies
Junko Ozao-Choy et al.
CANCER RESEARCH (2009)
Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells
Hong Xin et al.
CANCER RESEARCH (2009)
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
Jennifer S. Ko et al.
CLINICAL CANCER RESEARCH (2009)
The Cooperative Induction of Hypoxia-Inducible Factor-1α and STAT3 during Hypoxia Induced an Impairment of Tumor Susceptibility to CTL-Mediated Cell Lysis
Muhammad Zaeem Noman et al.
JOURNAL OF IMMUNOLOGY (2009)
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
S. Mustjoki et al.
LEUKEMIA (2009)
SEVERE HEMORRHAGIC COLITIS CAUSED BY DASATINIB IN PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Tomoyuki Shimokaze et al.
PEDIATRIC HEMATOLOGY AND ONCOLOGY (2009)
Validation of PDGFRβ and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma:: preclinical efficacy of the novel, orally available inhibitor dasatinib
Addolorata Maria Luce Coluccia et al.
BLOOD (2008)
Profound inhibition of antigen-specific T-cell effector functions by dasatinib
Ralf Weichsel et al.
CLINICAL CANCER RESEARCH (2008)
Hypoxia-Adenosinergic Immunosuppression: Tumor Protection by T Regulatory Cells and Cancerous Tissue Hypoxia
Michail V. Sitkovsky et al.
CLINICAL CANCER RESEARCH (2008)
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma
Sergio A. Quezada et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function
Ping-Ying Pan et al.
BLOOD (2008)
Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects
Faye M. Johnson et al.
CLINICAL CANCER RESEARCH (2007)
Processing and presentation of tumor antigens and vaccination strategies
P van der Bruggen et al.
CURRENT OPINION IN IMMUNOLOGY (2006)
An autologous oral DNA vaccine protects against murine melanoma
R Xiang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
